Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
JAMA. 2023 Feb 7;329(5):376-385. doi: 10.1001/jama.2022.25029.
JAMA. 2023.
PMID: 36749332
Free PMC article.
Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Hutton DW, Glassman AR, Liu D, Sun JK; DRCR Retina Network.
Hutton DW, et al.
JAMA Ophthalmol. 2023 Mar 1;141(3):268-274. doi: 10.1001/jamaophthalmol.2022.6142.
JAMA Ophthalmol. 2023.
PMID: 36729431
Free PMC article.
Clinical Trial.
Item in Clipboard
Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Jhaveri CD, Glassman AR, Ferris FL 3rd, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK; DRCR Retina Network.
Jhaveri CD, et al.
N Engl J Med. 2022 Aug 25;387(8):692-703. doi: 10.1056/NEJMoa2204225. Epub 2022 Jul 14.
N Engl J Med. 2022.
PMID: 35833805
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite